Key result
Treatment for childhood acute leukemia was associated with one or more adverse late effects in 74.1% of survivors over a mean follow-up of 5.3 years.
Cohort (n=324)
No
Childhood acute leukemia survivors experience a high rate (74.1%) of late adverse events, including cardiac abnormalities and hypertension, underscoring the need for lifelong monitoring.
May warrant enhanced cardiac surveillance in survivors; leaves open optimal protocols and intervention impact.
BACKGROUND: This is a report of late effects in childhood cancer survivors seen in the follow-up clinic of a single institution. MATERIALS AND METHODS: There were 324 acute leukemia survivors in the database of the Long Term Follow Up Clinic of Children's National Medical Center from January 1, 1997, through June 30, 2005. RESULTS: Of the 324 acute leukemia survivors, 228 were white, 48 black, 20 Hispanic, and 12 other. Their follow-up time was 0 to 25 years (mean 5.3 years). One or more adverse events occurred in 74.1% of the 324 survivors. Defective physical growth was most commonly reported, followed by disturbed neurocognitive function, emotional difficulties, cardiac abnormalities, hypertension, osteoporosis/osteopenia, fractures, and second neoplasms. More black and Hispanic children had acute myeloid leukemia, relapses, cardiac problems, and hypertension than white and other subjects. CONCLUSION: Childhood cancer survivors require lifelong monitoring, with prompt identification and treatment of adverse late effects.
No takes yet. Share an insight, caveat, or question.
Haddy et al. (2009) conducted a cohort in Childhood acute leukemia survivors (n=324). Treatment for childhood acute leukemia was evaluated on One or more adverse events. Treatment for childhood acute leukemia was associated with one or more adverse late effects in 74.1% of survivors over a mean follow-up of 5.3 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: